Investing
The company's technology looks to reduce the burden on pathologists reviewing digital slides, while also serving as a safety net to reduce errors.
The deal is expected to close in the second quarter of 2021. It will value the combined company at approximately $1.1 billion.
Also: Valo Health closes $300 million for machine learning drug discovery; Blue Note Therapeutics supports its in-development prescription DTx with $26.25 million.
Investment firm Kuwait Life Sciences Company's Dr. Mussaad M. Al-Razouki gives a breakdown of recently filed or finalized digital health SPACs, as well as a list of unicorns ripe for a potential merger.
Also: Oscar Health IPO dips below expectations; DrChrono's new "all-in-one telehealth app experience."
The Israeli startup raised the first $50 million in April 2020 in a round led by Insight Partners, which led this extension as well.
This brings the company's total valuation to $1.7 billion.
The company is initially targeting the large employer market with its app-connected biometric monitoring tools.
The company currently manages one million lives, and plans to expand its footprint with the new funds.
The investment from "a leading national Integrated Delivery Network" brings the Series D's total to $100 million.